ImmunoGen, Inc. (IMGN: Quote) announced that the Investigational New Drug, or IND, application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, non-small cell lung cancer and other epithelial malignancies which over-express folate receptor 1, or FOLR1.
The company expects Phase I evaluation of IMGN853 to commence in the middle of 2012.
Daniel Junius, president and chief executive officer, commented, "Our progress with IMGN901, IMGN529 and now IMGN853 speaks to our commitment to build and effectively advance a product pipeline of significant anticancer therapeutics. Each of these product candidates employs our TAP technology with its specific design optimized for its target. IMGN853, for example, uses one of the novel linkers we engineered to counter the multi-drug resistance that cancer cells can develop. Given the expression patterns of its target, with IMGN853 we also have a diagnostic assay to help in the identification of the patients most likely to benefit from treatment."
Click here to receive FREE breaking news email alerts for Immunogen Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org